Malignant Pleural Mesothelioma Market Drug Class (Premetrexed and Combination, Cisplatin and Combination, Carboplatin and Combination, Gemcitabine and Combination, Vinorelbine and Combination and Other Combination), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Oncology Centers), By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Trend Analysis, Competitive Market Share & Forecast, 2016-26
- Published Date: March 2020
- Report ID: BWC19437
- Available Format: PDF
- Page: 180
Report Overview
Global
Malignant Pleural Mesothelioma Market Forecast and Trends
The global Malignant Pleural
Mesothelioma market has reached USD Billion in 2019 and estimated to reach USD
Billion in 2026 and anticipated to grow by CAGR of 7.6% during the forecast
period 2020-2026. The global market for malignant pleural mesothelioma will
likely incur a favorable boost from increased healthcare spending seen in
multiple parts of the world, coupled with the availability of better treatment
prognosis for malignant pleural mesothelioma. Overall, the global malignant
mesothelioma market is also seeing increased adoption of combination therapies.
In the treatment of malignant pleural mesothelioma, many companies promote the
increasing use of chemotherapy and immune-oncology procedures.
Global
Malignant Pleural Mesothelioma Market: Overview
Malignant pleural
mesothelioma is a rare and aggressive cancer that develops around the lungs in
a thin layer of tissue called pleura. The microscopic inhalation of asbestos
fibers causes malignant pleural mesothelioma. Once the person is inhaling
asbestos particles, the human body fails to remove asbestos needle-like fibers
from the lungs. The incidence of
malignant pleural mesothelioma in Europe is around 20 per million inhabitants,
according to the NIH, and it is increasing globally. This will then require the
need to develop innovative treatments for malignant pleural mesothelioma, which
will drive market growth. Malignant pleural mesothelioma signs include dyspnea,
recurrent dry or raspy cough, chest pain, difficulty swallowing, also known as
dysphagia, and also known as hemoptysis, coughing up the blood. Since the mid
20th century, the occurrence of Malignant pleural mesothelioma has increased.
The appearance of malignant pleural mesothelioma within and between nations is
markedly variable.
Growth
Drivers
Rising exposure to asbestos
(industrial pollutant)
People exposed to asbestos
are at a higher risk of developing malignant pleural mesothelioma. Within
contaminated areas, the chance of malignant pleural mesothelioma is increased
by 2 to 10 fold as compared with non-polluted areas. Besides, people exposed to
a high dose of radiation, zeolites (minerals chemically associated with
asbestos), and suffering from simian virus 40 are at risk of developing
malignant pleural mesothelioma and indirectly contribute to the global market
for malignant pleural mesothelioma with the significant growth rate.
Increasing expenditure on
R&D coupled with increasing pipeline molecule
The therapeutic pipeline is
expected to see significant growth in the forthcoming years on the market for
malignant pleural mesothelioma due to higher incidence rates, increased air
pollution, increased geriatric population, and increased healthcare
expenditure. In addition, the advancement of innovative therapy and the launch
of advanced treatment options are likely to provide the malignant pleural
mesothelioma market with lucrative growth opportunities over the 2020-2026
forecast period.
Restraint
Delay in Diagnosis
The key factor expected to
hamper the growth of the global market for malignant pleural mesothelioma is a
long latent period between onset and symptom, lack of effective treatment, and
low surveillance rates over the 202-2026 forecast period.
Global
Malignant Pleural Mesothelioma Market: Drug Class
Based on drug class, the global malignant pleural mesothelioma market segmented into Premetrexed and Combination, Cisplatin and Combination, Carboplatin and Combination, Gemcitabine, and Combination, Vinorelbine and Combination and Other Combination. Among the group is considered a combination of pemetrexed and cisplatin as the normal first-line treatment of malignant pleural mesothelioma. It is the most effective treatment for Chemotherapy. In a recent study to test cisplatin and pemetrexed called Mesothelioma Avastin Cisplatin Pemetrexed Trial (MAPS), the addition of bevacizumab showed significantly improved survival rates for patients with minimal side effects of malignant pleural mesothelioma.
Global
Malignant Pleural Mesothelioma Market: Distribution Channel
Based on Distribution
Channel, the market is diversified as hospital pharmacies, retail pharmacies,
and oncology centers. Amidst the category oncology centers expected to cater
global malignant pleural mesothelioma market with a high growth rate. Followed
by oncology centers, hospital pharmacies, and retail pharmacies anticipated to
witness significant growth rate during the forecast period of 2020-2026.
Global
Malignant Pleural Mesothelioma Market: Regional Insights
Global Malignant Pleural Mesothelioma market segmented into five regions, including North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is leading the market for malignant pleural mesothelioma, followed by Europe due to higher incidence and prevalence rates, an increase in the geriatric population, and increased demand advance therapy. The Asia Pacific is an emerging market for malignant pleural mesothelioma due to the development of healthcare infrastructure, patient awareness, and increased government spending in the healthcare sector. Low recognition of patients, lack of proper care, and high therapy costs are factors that narrow the Middle East & Africa market for malignant pleural mesotheliomas.
Malignant
Pleural Mesothelioma: Competitive Landscape
Malignant Pleural
Mesothelioma market is fragmented owing to the presence of number of
large-sized companies that hold the majority share of AstraZeneca Plc.,
Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc.,
Novartis AG, Pfizer Inc., Sanofi, Eli Lilly and Company, Teva Pharmaceuticals,
Boehringer Ingelheim GmbH, Mylan N.V., Fresenius Kabi AG, Sun Pharmaceuticals
Industries Ltd, Corden Pharma International GmbH, Concordia International Corp
and Other Prominent Players.
The
objective of the Study:
To analyze and forecast the
global market size of the Malignant Pleural Mesothelioma.
Analyzing careful market
segmentation and estimating value-based market size through region-based
segmentation.
The global Malignant Pleural
Mesothelioma is divided into five regions: North America, Europe, Asia-Pacific,
Middle East & Africa, Latin America.
To outline, categorize, and
forecast the global AI in the agricultural market based on drug class, route of
administration, and distribution channel with the region.
To examine competitive
developments in the global Malignant Pleural Mesothelioma market, such as
technological advancement, services, and regulatory framework.
To emphasize the impact
study of market dynamics variables such as users, constraints, opportunities,
and challenges.
Profiling key players
strategically and analyzing their market shares comprehensively, together with
detailing the competitive environment for market leaders.
Scope of the Report:
|
Attribute |
Details |
|
Years Considered |
Historical data – 2016-2019 |
|
Base Year – 2019 |
|
|
Forecast – 2020 – 2026 |
|
|
Facts Covered |
Revenue in USD Million/Billion |
|
Market Coverage |
U.S, Canada, Germany, UK, France, Italy, Spain, Brazil, Mexico,
Argentina, Japan, South Korea, China, India, UAE, South Africa, Saudi Arabia |
|
Product/Service Segmentation |
By Drug Class, Route of Administration, and Distribution
Channel |
|
Key Players |
AstraZeneca Plc., Bristol-Myers Squibb Company, F. Hoffmann-La
Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Eli
Lilly and Company, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan NV,
Fresenius Kabi AG, Sun Pharmaceuticals Industries Ltd, Corden Pharma
International GmbH, Concordia International Corp, Other Prominent Players. |
By Drug Class
·
Pemetrexed and Combination
·
Cisplatin and Combination
·
Carboplatin and Combination
·
Gemcitabine and Combination
·
Vinorelbine and Combination
·
Other Combination
By Route of Administration
·
Oral
·
Parenteral
By Distribution Channel
·
Hospital Pharmacies
·
Retail Pharmacies
·
Oncology Centers
By Region:
·
North America
·
Europe
·
Asia Pacific
·
Latin America
·
Middle East & Africa
Business
Questions Answer by the Report
How will the market drivers,
restraints, and opportunities affect the market dynamics?
What will be the market size
in terms of value and volume and market statistics with a detailed classification?
Which segment dominates the
market or region, and one will be the fastest-growing, and why?
A comprehensive survey of
the competitive landscape and the market participant players
Analysis of strategy adopted
by the key player and their impact on other players.
Customization
Scope for the Client
Client satisfaction is our
first and last priority, and that’s why BlueWeave Consulting offers
customization according to Company’s specific needs. The following
customization options are available for the report:
Additional
Company Information
With five additional company
detail analysis
Additional country analysis
Detailed segment analysis
1. Research Framework
1.1. Research
Objective
1.2. Product
Overview
1.3. Market
Segmentation
2. Research Methodology
2.1. Qualitative
Research
2.1.1.
Primary & Secondary Sources
2.2. Quantitative
Research
2.2.1.
Primary & Secondary Sources
2.3. Breakdown
of Primary Research Respondents, By Region
2.3.1.
Secondary Research
2.3.2.
Primary Research
2.4. Breakdown
of Primary Research Respondents
2.5. Market
Size Estimation
2.6. Assumption
for The Study
2.7. Market
Breakdown & Data Triangulation
3. Executive Summary
4. Global Malignant Pleural Mesothelioma
Insights
4.1. DROC
Analysis
4.1.1.
Growth Drivers
4.1.2.
Restraints
4.1.3.
Opportunities
4.1.4.
Challenges
4.2. Technological
Landscape
4.3. Regulatory
Framework
4.4. Company
Market Share Analysis, 2019
4.5. Porter’s
Five forces analysis
4.5.1.
Bargaining Power of Suppliers
4.5.2.
Bargaining Power of Buyers
4.5.3.
Threat of New Entrants
4.5.4.
Threat of Substitutes
4.5.5.
Intensity of Rivalry
5. Global Malignant Pleural Mesothelioma
Market Overview
5.1. Market
Size & Forecast by Value, 2016-2026
5.1.1.
By Value (USD Million)
5.2. Market
Share & Forecast 2016-2026
5.2.1.
By Route of Administration
5.2.1.1.
Oral
5.2.1.2.
Parenteral
5.2.2.
By Drug Class
5.2.2.1.
Pemetrexed and Combination
5.2.2.2.
Cisplatin and Combination
5.2.2.3.
Carboplatin and Combination
5.2.2.4.
Gemcitabine and Combination
5.2.2.5.
Vinorelbine and Combination
5.2.2.6.
Other Combination
5.2.3.
By Distribution Channel
5.2.3.1.
Hospital Pharmacies
5.2.3.2.
Retail Pharmacies
5.2.3.3.
Oncology Centers
5.2.4.
By Region
5.2.4.1.
North America
5.2.4.2.
Europe
5.2.4.3.
Asia Pacific
5.2.4.4.
Latin America
5.2.4.5.
Middle East & Africa
6. North America Malignant Pleural
Mesothelioma Market
6.1. Market
Size & Forecast by Value, 2016-2026
6.1.1.
By Value (USD Million)
6.2. Market
Share & Forecast 2016-2026
6.2.1.
By Route of Administration
6.2.2.
By Drug Class
6.2.3.
By Distribution Channel
6.2.4.
By Country
6.2.4.1.
U.S
6.2.4.2.
Canada
7. Europe Malignant Pleural Mesothelioma
Market
7.1. Market
Size & Forecast by Value, 2016-2026
7.1.1.
By Value (USD Million)
7.2. Market
Share & Forecast 2016-2026
7.2.1.
By Route of Administration
7.2.2.
By Drug Class
7.2.3.
By Distribution Channel
7.2.4.
By Country
7.2.4.1.
Germany
7.2.4.2.
U.K
7.2.4.3.
France
7.2.4.4.
Italy
7.2.4.5.
Spain
7.2.4.6.
Rest of Europe
8. Asia Pacific Malignant Pleural
Mesothelioma Market
8.1. Market
Size & Forecast by Value, 2016-2026
8.1.1.
By Value (USD Million)
8.2. Market
Share & Forecast 2016-2026
8.2.1.
By Route of Administration
8.2.2.
By Drug Class
8.2.3.
By Distribution Channel
8.2.4.
By Country
8.2.4.1.
China
8.2.4.2.
India
8.2.4.3.
Japan
8.2.4.4.
South Korea
8.2.4.5.
Rest of Asia Pacific
9. Latin America Malignant Pleural
Mesothelioma Market
9.1. Market
Size & Forecast by Value, 2016-2026
9.1.1.
By Value (USD Million)
9.2. Market
Share & Forecast 2016-2026
9.2.1.
By Route of Administration
9.2.2.
By Drug Class
9.2.3.
By Distribution Channel
9.2.4.
By Country
9.2.4.1.
Brazil
9.2.4.2.
Mexico
9.2.4.3.
Argentina
9.2.4.4.
Rest of Latin America
10. Middle
East & Africa Malignant Pleural Mesothelioma Market
10.1.
Market Size & Forecast by Value,
2016-2026
10.1.1.
By Value (USD Million)
10.2.
Market Share & Forecast 2016-2026
10.2.1.
By Route of Administration
10.2.2.
By Drug Class
10.2.3.
By Distribution Channel
10.2.4.
By Country
10.2.4.1.
Saudi Arabia
10.2.4.2.
UAE
10.2.4.3.
South Africa
10.2.4.4.
Rest of Middle East & Africa
11.Company Profile (Company Overview,
Financial Matrix, Product landscape, Key Personnel, Key Competitors, Contact
Address, and Strategic Outlook) *
11.1.
AstraZeneca Plc.
11.2.
Bristol-Myers Squibb Company
11.3.
F. Hoffmann-La Roche Ltd.
11.4.
Merck & Co., Inc.
11.5.
Novartis AG
11.6.
Pfizer Inc.
11.7.
Sanofi
11.8.
Eli Lilly and Company
11.9.
Teva Pharmaceuticals
11.10.
Boehringer Ingelheim GmbH
11.11.
Mylan NV.
11.12.
Fresenius Kabi AG
11.13.
Sun Pharmaceuticals Industries Ltd
11.14.
Corden Pharma International GmbH
11.15.
Concordia International Corp
11.16.
Other Prominent Players
List
of Figures:
Fig: Global Malignant
Pleural Mesothelioma Segmentation
Fig: Company Market Share
Analysis, 2019
Fig: Global Malignant
Pleural Mesothelioma Market Size, By Value (USD Million), 2016-2026
Fig: Global Malignant
Pleural Mesothelioma Market Share, By Route of Administration, By Value,
2016-2026
Fig: Global Malignant
Pleural Mesothelioma Market Share, By Drug Class, By Value, 2016-2026
Fig: Global Malignant
Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2016-2026
Fig: Global Malignant
Pleural Mesothelioma Market Share, By Region, By Value, 2016-2026
Fig: North America Malignant
Pleural Mesothelioma Market Size, By Value (USD Million), 2016-2026
Fig: North America Malignant
Pleural Mesothelioma Market Y-o-Y Growth, By Value, 2017-2026
Fig: North America Malignant
Pleural Mesothelioma Market Share, By Route of Administration, By Value,
2016-2026
Fig: North America Malignant
Pleural Mesothelioma Market Share, By Drug Class, By Value, 2016-2026
Fig: North America Malignant
Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2016-2026
Fig: North America Malignant
Pleural Mesothelioma Market Share, By Country, By Value, 2016-2026
Fig: Europe Malignant
Pleural Mesothelioma Market Size, By Value (USD Million), 2016-2026
Fig: Europe Malignant
Pleural Mesothelioma Market Y-o-Y Growth, By Value, 2017-2026
Fig: Europe Malignant
Pleural Mesothelioma Market Share, By Route of Administration, By Value,
2016-2026
Fig: Europe Malignant
Pleural Mesothelioma Market Share, By Drug Class, By Value, 2016-2026
Fig: Europe Malignant
Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2016-2026
Fig: Europe Malignant
Pleural Mesothelioma Market Share, By Country, By Value, 2016-2026
Fig: Asia-Pacific Malignant
Pleural Mesothelioma Market Size, By Value (USD Million), 2016-2026
Fig: Asia-Pacific Malignant
Pleural Mesothelioma Market Y-o-Y Growth, By Value, 2017-2026
Fig: Asia-Pacific Malignant
Pleural Mesothelioma Market Share, By Route of Administration, By Value,
2016-2026
Fig: Asia-Pacific Malignant
Pleural Mesothelioma Market Share, By Drug Class, By Value, 2016-2026
Fig: Asia-Pacific Malignant
Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2016-2026
Fig: Asia-Pacific Malignant
Pleural Mesothelioma Market Share, By Country, By Value, 2016-2026
Fig: Latin America Malignant
Pleural Mesothelioma Market Size, By Value (USD Million), 2016-2026
Fig: Latin America Malignant
Pleural Mesothelioma Market Y-o-Y Growth, By Value, 2017-2026
Fig: Latin America Malignant
Pleural Mesothelioma Market Share, By Route of Administration, By Value,
2016-2026
Fig: Latin America Malignant
Pleural Mesothelioma Market Share, By Drug Class, By Value, 2016-2026
Fig: Latin America Malignant
Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2016-2026
Fig: Latin America Malignant
Pleural Mesothelioma Market Share, By Country, By Value, 2016-2026
Fig: Middle-East &
Africa Malignant Pleural Mesothelioma Market Size, By Value (USD Million),
2016-2026
Fig: Middle-East &
Africa Malignant Pleural Mesothelioma Market Y-o-Y Growth, By Value, 2017-2026
Fig: Middle East &
Africa Malignant Pleural Mesothelioma Market Share, By Route of Administration,
By Value, 2016-2026
Fig: Middle East &
Africa Malignant Pleural Mesothelioma Market Share, By Drug Class, By Value,
2016-2026
Fig: Middle East &
Africa Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By
Value, 2016-2026
Fig: Middle East &
Africa Malignant Pleural Mesothelioma Market Share, By Country, By Value,
2016-2026
List
of Tables:
Table: Global Malignant
Pleural Mesothelioma Market Size, By Route of Administration, By Value,
2016-2026
Table: Global Malignant
Pleural Mesothelioma Market Size, By Drug Class, By Value, 2016-2026
Table: Global Malignant
Pleural Mesothelioma Market Size, By Distribution Channel, By Value, 2016-2026
Table: Global Malignant
Pleural Mesothelioma Market Size, By Region, By Value, 2016-2026
Table: North America
Malignant Pleural Mesothelioma Market Size, By Route of Administration, By
Value, 2016-2026
Table: North America
Malignant Pleural Mesothelioma Market Size, By Drug Class, By Value, 2016-2026
Table: North America
Malignant Pleural Mesothelioma Market Size, By Distribution Channel, By Value,
2016-2026
Table: North America
Malignant Pleural Mesothelioma Market Size, By Country, By Value, 2016-2026
Table: Europe Malignant
Pleural Mesothelioma Market Size, By Route of Administration, By Value,
2016-2026
Table: Europe Malignant
Pleural Mesothelioma Market Size, By Drug Class, By Value, 2016-2026
Table: Europe Malignant
Pleural Mesothelioma Market Size, By Distribution Channel, By Value, 2016-2026
Table: Europe Malignant
Pleural Mesothelioma Market Size, By Country, By Value, 2016-2026
Table: Asia-Pacific
Malignant Pleural Mesothelioma Market Size, By Route of Administration, By
Value, 2016-2026
Table: Asia-Pacific
Malignant Pleural Mesothelioma Market Size, By Drug Class, By Value, 2016-2026
Table: Asia-Pacific
Malignant Pleural Mesothelioma Market Size, By Distribution Channel, By Value,
2016-2026
Table: Asia-Pacific
Malignant Pleural Mesothelioma Market Size, By Country, By Value, 2016-2026
Table: Latin America
Malignant Pleural Mesothelioma Market Size, By Route of Administration, By
Value, 2016-2026
Table: Latin America
Malignant Pleural Mesothelioma Market Size, By Drug Class, By Value, 2016-2026
Table: Latin America
Malignant Pleural Mesothelioma Market Size, By Distribution Channel, By Value,
2016-2026
Table: Latin America
Malignant Pleural Mesothelioma Market Size, By Country, By Value, 2016-2026
Table: Middle East &
Africa Malignant Pleural Mesothelioma Market Size, By Route of Administration,
By Value, 2016-2026
Table: Middle East &
Africa Malignant Pleural Mesothelioma Market Size, By Drug Class, By Value,
2016-2026
Table: Middle East &
Africa Malignant Pleural Mesothelioma Market Size, By Distribution Channel, By
Value, 2016-2026
Table: Middle East &
Africa Malignant Pleural Mesothelioma Market Size, By Country, By Value,
2016-2026
Table: AstraZeneca Plc.
Financial Analysis
Table: Bristol-Myers Squibb
Company Financial Analysis
Table: F. Hoffmann-La Roche
Ltd. Financial Analysis
Table: Merck & Co., Inc.
Financial Analysis
Table: Novartis AG Financial
Analysis
Table: Pfizer Inc. Financial
Analysis
Table: Sanofi Financial
Analysis
Table: Eli Lilly and Company
Financial Analysis
Table: Teva Pharmaceuticals
Financial Analysis
Table: Boehringer Ingelheim
GmbH Financial Analysis
Table: Mylan NV. Financial
Analysis
*Financial Information of
non-listed companies will be provided as per the availability
**The segmentation and the
companies are subjected to modification based on the in-depth secondary for the
final deliverable.
Market Segmentation
By Drug Class
· Pemetrexed and Combination
· Cisplatin and Combination
· Carboplatin and Combination
· Gemcitabine and Combination
· Vinorelbine and Combination
· Other Combination
By Route of Administration
· Oral
· Parenteral
By Distribution Channel
· Hospital Pharmacies
· Retail Pharmacies
· Oncology Centers
By Region:
· North America
· Europe
· Asia Pacific
· Latin America
· Middle East & Africa
To request a free sample copy of this report, please complete the form below.
We value your investment and offer free customization with every report to fulfil your exact research needs.
RELATED REPORTS
WHY CHOOSE US
-
24/7 Research support
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
-
Coustom Research Service
Ask the Analyst to customize an exclusive study to serve your research needs
-
Quality & Accuracy
Ask the Analyst to customize an exclusive study to serve your research needs
-
Data Visualization
As the business world is changing dynamically every day. We need to stay pin point in relation to data management and optimum data utilization
-
Information security
We never share your personal and confidential information. Your personal information is safe and secure with us.